Company: XAIR
Filing Date: 2025-06-20
Form Type: 10-K
Source: 0001641172-25-015750
Chunk: 1195

Company: Beyond Air, Inc.
Filing Date: 2025-06-20
Form: 10-K
Item: Item 1C
Chunk 1195
---
 Air a single digit royalty on all future revenues.

The carrying amount of
NeuroNos’ net assets included in the consolidated financial statements, after the elimination of intercompany balances and transactions,
was $2.0
million at March 31, 2025. NeuroNos generated $0.8
million of losses (before elimination of intercompany amounts) for the year ended March 31, 2025. The Company’s attributed
losses as the primary beneficiary was proportional to its equity interest in NeuroNos (88.24%)
for the year ended March 31, 2025.

The following table summarizes segment financial information
by business segment for the year ended and at March 31, 2025:

 SCHEDULE
OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT

    (in thousands) 
    Beyond Air  
    Beyond Cancer  
     NeuroNos  
    Total 
  
    Cash, cash equivalents and marketable securities 
    $2,750  
    $2,167  
    $2,000  
    $6,917 
  
    All other assets 
     22,116  
     1,029  
     -  
     23,145 
  
    Total assets 
    $24,866  
    $3,196  
    $2,000  
    $30,062 
  
    Total liabilities 
     (15,082) 
     (589) 
     (50) 
     (15,721)
  
    Net assets 
    $9,784  
    $2,607  
    $1,950  
    $14,341 
  
    Non-controlling interest 
    $-  
    $529  
    $229  
    $758 
  
    Capital expenditures 
    $5,859  
    $24  
    $-  
    $5,883 

    Revenues 
    $3,705  
    $-  
    $-  
    $3,705 
  
    Cost of revenues 
     (5,368) 
     -  
     -  
     (5,368)
  
    Research and development 
     (13,780) 
     (3,062) 
     (15) 
     (16,857)
  
    Selling, general, and administrative